Compare Kainos Laboratories, Inc. with Similar Stocks
Dashboard
1
Company has very low debt and has enough cash to service the debt requirements
2
Poor long term growth as Net Sales has grown by an annual rate of 2.85% over the last 5 years
3
Flat results in Dec 25
4
With ROE of 9.46%, it has a very attractive valuation with a 0.83 Price to Book Value
5
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 6,063 Million (Micro Cap)
9.00
NA
0.00%
-0.40
8.36%
0.87
Revenue and Profits:
Net Sales:
1,434 Million
(Quarterly Results - Dec 2025)
Net Profit:
141 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
78.97%
0%
78.97%
6 Months
84.68%
0%
84.68%
1 Year
97.81%
0%
97.81%
2 Years
123.49%
0%
123.49%
3 Years
129.87%
0%
129.87%
4 Years
76.86%
0%
76.86%
5 Years
96.94%
0%
96.94%
Kainos Laboratories, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.85%
EBIT Growth (5y)
6.49%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.42
Sales to Capital Employed (avg)
0.73
Tax Ratio
22.50%
Dividend Payout Ratio
23.02%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.37%
ROE (avg)
9.80%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.83
EV to EBIT
3.35
EV to EBITDA
2.98
EV to Capital Employed
0.71
EV to Sales
0.53
PEG Ratio
6.25
Dividend Yield
NA
ROCE (Latest)
21.08%
ROE (Latest)
9.46%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
1,434.20
1,336.10
7.34%
Operating Profit (PBDIT) excl Other Income
198.60
190.10
4.47%
Interest
1.60
1.40
14.29%
Exceptional Items
0.10
25.00
-99.60%
Consolidate Net Profit
140.50
122.60
14.60%
Operating Profit Margin (Excl OI)
120.70%
123.90%
-0.32%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 7.34% vs -6.70% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 14.60% vs -33.26% in Sep 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
5,305.60
5,056.50
4.93%
Operating Profit (PBDIT) excl Other Income
919.50
977.00
-5.89%
Interest
6.60
7.00
-5.71%
Exceptional Items
0.00
11.20
-100.00%
Consolidate Net Profit
641.00
638.00
0.47%
Operating Profit Margin (Excl OI)
155.20%
171.10%
-1.59%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 4.93% vs 2.71% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 0.47% vs 12.28% in Mar 2024
About Kainos Laboratories, Inc. 
Kainos Laboratories, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






